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Despite the advent of new drug classes, the global epidemic of cardiometabolic disease has not abated.
Continuing unmet medical needs remain a major driver for new research. Drug discovery approaches in
this field have mirrored industry trends, leading to a recent increase in the number of molecules entering
development. However, worrisome trends and newer hurdles are also apparent. The history of two newer
drug classes—glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors—illustrates
both progress and challenges. Future success requires that researchers learn from these experiences and
continue to explore and apply new technology platforms and research paradigms.Introduction
The global epidemic of obesity and diabetes continues to prog-
ress relentlessly. The International Diabetes Federation predicts
an even greater diabetes burden (>430 million people afflicted)
by 2030, which will disproportionately affect developing nations
(International Diabetes Federation, 2011). Yet existing drug
classes for diabetes, obesity, and comorbid cardiovascular
(CV) conditions have substantial limitations.
Currently available prescription drugs for treatment of hyper-
glycemia in patients with type 2 diabetes (Table 1) have notable
shortcomings. In general, their efficacy profiles fall short of
achieving accepted treatment goals (American Diabetes Associ-
ation, 2011). Therefore, clinicians must often use combination
therapy, adding additional agents over time. Ultimately many
patients will need to use insulin—a therapeutic class first intro-
duced in 1922. Most existing agents also have issues around
safety and tolerability as well as dosing convenience (which
can impact patient compliance).
Future therapies must focus on unmet medical needs in the
following ways: (1) they must have mechanisms that can safely
achieve greater glycemic efficacy; (2) they must mitigate the
CV risk associated with diabetes, obesity, and dyslipidemia; (3)
they should help patients with or at-risk of diabetes to achieve
meaningful and safe weight loss; and (4) they should attenuate
the progression of microvascular complications. For diabetes
and obesity in particular, an overriding need exists for true
disease-modifying agents that deliver longer term benefits—to
prevent disease and/or disease progression. In examining the
extent to which existing therapies address these needs, consider
the fact that pharmacotherapy for obesity has been available in
the U.S. since the FDA approval of amphetamine sulfate (Benze-
drine) in 1939. Yet, after many intervening episodes of transient
success and spectacular failure, today there are only two
approved (U.S.) weight-loss agents, orlistat and phentermine,
both with limited effectiveness. Phentermine is only indicated
for transient use, whereas treatment of metabolic disease gener-
ally requires lifelong intervention! Moreover, improvements in
glucose control over the past 20 years have been generally
modest. Even in a wealthy developed nation like the U.S.,more than 40% of patients diagnosed with diabetes do not
achieve accepted glycemic goals (Hoerger et al., 2008); an
even greater proportion (80%) fail to also achieve critical goals
pertaining to blood pressure and lipids.
The confluence of an expanding epidemic, limitations of
current drugs, and compelling unmet medical needs provide
a strong rationale for continued emphasis on finding and devel-
oping novel therapeutic approaches.
The Current Paradigm
Tools from modern biology and an understanding of pathophys-
iology have lead to a common model for drug discovery and
development (Milne, 2008; Kola, 2008; Paul et al., 2010)
(Figure 1). R&D efforts aimed at metabolic disease have largely
mirrored industry trends in this regard.
Most projects focus on individual drug ‘‘targets’’: discrete
gene products/proteins (Yang et al., 2009). However, strict
adherence to the single-target approach may be ill-advised
since all older and even many newer (since 1999) drug classes
were discovered using phenotypic screening, without initial
knowledge of a defined molecular target (Swinney and Anthony,
2011).
Screening technologies and chemistry trends have driven the
selection of targets toward ‘‘drugable’’ classes. Contemporary
examples include enzymes (e.g., glucokinase), circulating
proteins such as cholesterol ester transfer protein (CETP), and
cell-surface receptors (e.g., glucagon receptor). Peptides and
larger circulating proteins are also popular targets for biomole-
cules (e.g., peptide YY, ghrelin, fibroblast growth factor 21
[FGF21], and proprotein convertase subtilisin/kexin type 9
[PCSK9]).
‘‘Target validation’’ is the buzzword for establishing links
between the target and human disease. This includes human
genetic association, regulation of expression in the context of
disease, phenotypes detected in transgenic or knockout mice,
consequences of siRNA-mediated gene knockdown, and phar-
macology in animals or early clinical testing (Yang et al., 2009;
Milne, 2009; Libby et al., 2011). Validation is best seen as a
continuum. For example, early validation via a knockout mouseCell Metabolism 15, January 4, 2012 ª2012 Elsevier Inc. 19
Table 1. Major Existing Drug Classes Approved for Therapy of Hyperglycemia in Patients with Type 2 Diabetes (Excluding Insulin
Products)
Drug Class (Examples) Molecular Mechanism Efficacy Profile (D Hb A1c*) Adverse Effects/Tolerability (other)
Sulfonylureas (glyburide, glipizide,
glimepiride) and meglitinides
(nateglinide, repaglinide)
K+-ATP channel modulator
(insulin secretion)
Moderate-good - but lacking
long term durability
(0.7%–1.3%)
Hypoglycemia; weight gain;
3 doses per day with meglitinides
Metformin Unknown Moderate (0.7%–1.0%) Gastrointestinal symptoms;
twice-daily dosing; lactic
acidosis (rare); contraindicated
with reduced renal function
Thiazolidinediones
(pioglitazone, rosiglitazone)
PPARg agonist
(insulin sensitization)
Moderate (0.6%–1.1%) Weight gain, edema, exacerbation
of heart failure, increased bone
fractures; possible increased
bladder cancer (pioglitazone);
potential increased risk of
myocardial infarction (rosiglitazone)
a-glucosidase inhibitors
(acarbose)
Inhibition of intestinal
glucose absorption
Fair (0.4%–0.8%) Gastrointestinal symptoms
(frequent)
Incretin-mimetics
(exenatide; liraglutide)
GLP-1 receptor agonist Moderate-good (0.5%–1.3%);
plus modest weight loss
Daily or twice-daily injection required;
nausea and vomiting plus other
gastrointestinal symptoms; possible
increased risk of pancreatitis
Dipeptidyl-peptidase-4
inhibitors (sitagliptin,
saxagliptin, linagliptin)
Increased endogenous
GLP-1 and GIP levels
Fair (0.5%–0.8%) Hypersensitivity reactions (rare);
nasopharyngitis; upper respiratory
infection (infrequent); possible
increased risk of pancreatitis
Table information derived from US prescribing and label information for representative products available at http://www.FDA.gov. PPARg = peroxi-
some proliferator-activated receptor g. * Hb A1c = hemoglobin A1c (glycosylated hemoglobin); D Hb A1c ranges noted represent effects seen as
monotherapy and/or incremental when added to metformin.
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in animal models.
Once molecules that modulate target function are discovered
(screening and lead generation), ‘‘lead optimization’’ typically
follows. In this phase, many molecules are synthesized in an iter-
ative fashion seeking improved potency, selectivity, pharmaco-
kinetics, etc. Molecules selected for early development undergo
toxicology tests and initial (Phase I) human trials, but clear
signals of efficacy are usually not evident until the end of Phase
I or in Phase II.
The current process is long, arduous, and increasingly expen-
sive. Since earlier phases of drug discovery/development have
greater risks of failure, the number of molecules entering
Phase I must exceed the number of desired newmolecular entity
(NME) launches by an order of magnitude (Paul et al., 2010). The
daunting prospects for failure in preclinical phases demand
even greater numbers of basic research projects to supply new
Phase I opportunities.
Worrying Trends
The biopharmaceutical industry is facing an unprecedented
wave of patent expiries leading to a cumulative loss of U.S.
$78 billion in worldwide sales during 2010–2014 (Harrison,
2011). Drugs for diabetes and CV disease represented in this
cohort include atorvastatin, clopidogrel, and pioglitazone. These
and other macroeconomic forces, including rising healthcare
costs and pressure from third party payers, have created an
environment where new blockbusters are needed but funding
to support R&D is being curtailed.20 Cell Metabolism 15, January 4, 2012 ª2012 Elsevier Inc.A recent decline in total new drug approvals is worrisome.
Only 21 NMEs were approved by the FDA in 2010 and only 19
were approved in 2007, the lowest yearly total in 20 years
(Mullard, 2011). However, it is encouraging to note that new
approvals for the first half of 2011 have already matched the
2010 total.
Despite substantial industry investments, attrition rates for
pipeline molecules have not significantly improved. Thus, the
overall probability of success (POS) for molecules entering
Phase I remains low (%10%) and the aggregate average cost
to get a new drug approved is increasing (>$1 billion by current
estimates). Factors contributing to low productivity include (1)
increasing focus on disease areas characterized by lower POS,
oncology, and neuroscience in particular (Pammolli et al.,
2011; Kola, 2008); (2) research efforts oriented toward novel
poorly validated and ‘‘difficult’’ targets; (3) higher safety-regula-
tory hurdles; and (4) the requirement to achieve a clinical profile
that predicts commercial success. The poor track record in
translating efficacy in animal models to meaningful clinical effi-
cacy remains challenging. This occurs frequently in metabolic
disease drug development—especially when weight loss is the
desired clinical effect. Therefore, the major inflection point in
POS during drug development is in Phase II where definitive
proof-of-concept is typically established (Kola, 2008; Pammolli
et al., 2011; Paul et al., 2010; Milne, 2009).
Stringent regulatory requirements and specific CV safety
concerns are substantial hurdles for new diabetes drugs. Ques-
tions were raised by the Action to Control CV Risk in Diabetes
(ACCORD) trial, which showed increased CV mortality with
Figure 1. Roadmap for Common Practices in Current Drug Discovery/Development
Industry-based efforts focusing on cardiometabolic disease have largely mirrored the trends and approaches noted in this generic R&D paradigm.
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as well as by concerns pertaining to specific drugs such as
rosiglitazone (Hirshberg and Raz, 2011; Drucker and Goldfine,
2011). In response, recent FDA guidance mandates that new
antihyperglycemic drugs exclude significant CV risk prior to
initial approval (Hirshberg and Raz, 2011), thus requiring longer
(4 to 5 yr), larger (>5000 patient), and more costly (incremental
increase of $300 million) Phase III development programs.
An obvious consequence is that only companies with ‘‘deep
pockets’’ will have the resources to develop and launch diabetes
drugs. Hopefully, higher quality, safer drugs offering genuine CV
benefits may result despite fewer agents being selected for late
stage development.
Cases in Point
The history of glucagon-like peptide-1 (GLP-1) receptor agonists
and dipeptidyl peptidase-4 (DPP-4) inhibitors highlight important
aspects of the drug discovery process (Figure 2). The progluca-
gon gene, which encodes GLP-1, was cloned in 1982 (Lund
et al., 1982), several years after the discovery of another major
incretin—gastric inhibitory peptide (GIP); however, GLP-1’s
ability to potentiate glucose-stimulated insulin secretion in hu-
mans was not reported until 1987 (Kreymann et al., 1987).
Normalization of glucose in patients with type 2 diabetes by
exogenous GLP-1 was described thereafter (Nauck et al.,
1993), leading to intense interest in this hormone and its
surrounding pathways as potential targets of therapy (Deacon
and Holst, 2002; Drucker, 2006; Nauck, 2011; Hansen et al.,
2009). The ability of GLP-1 to promote weight loss and enhance
b cell mass and function in rodents added to the enthusiasm.A major challenge for developing native GLP-1 (or GIP) as
a drug was the finding that it is rapidly cleaved and inactivated
(via removal of two N-terminal residues) by DPP-4 (Mentlein
et al., 1993). This in vitro finding was ultimately confirmed in
animal and human studies (Deacon et al., 1995). Exendin-4,
a naturally occurring peptide, was isolated from the saliva of
Heloderma suspectum in the early 1990s (Eng et al., 1992). Its
characterization as an incretin-mimetic GLP-1 receptor agonist
resistant to degradation by DPP-4 was a key contribution to
the field (Drucker, 2006).
A decade of academic research lead to industry-based efforts
focused on the discovery of novel degradation-resistant incretin-
mimetic peptides and small molecule DPP-4 inhibitors, which
began in earnest in 1995–1996 (Figure 2). Since nomodifications
to the peptide were required, development of exendin-4 as
a twice-daily injectable therapy (exenatide) proceeded fairly
rapidly. Its clinical efficacy profile was defined in 2001–2004
(Fineman et al., 2003), and FDA approval was achieved in
2005. A second once-daily injectable human GLP-1 analog, lira-
glutide (Degn et al., 2004), was subsequently developed and
launched several years later (Jeong and Yoo, 2011). Other longer
acting forms of exenatide or GLP-1 analogs are now in develop-
ment (Nauck, 2011; Hansen et al., 2009).
The pursuit of small molecule DPP-4 inhibitors was aided by
the availability of ‘‘tool compounds’’ such as valine-pyrrolide,
which exert glycemic benefits in animals (Pauly et al., 1996;
Demuth et al., 2002). Initial concerns and issues surrounding
the DPP-4 mechanism, such as the potential for promiscuous
effects via regulation of substrates other than GLP-1 and
GIP and the importance of selectivity versus other prolylCell Metabolism 15, January 4, 2012 ª2012 Elsevier Inc. 21
2010500200020991 1995
Figure 2. Abbreviated Timeline of the Discovery and Development of GLP-1 Receptor Agonists and DPP-4 Inhibitors
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(Conarello et al., 2003; Lankas et al., 2005) in parallel with the
pursuit of novel and improved molecules. Early human proof-
of-concept was established in 2001–2002 (Ahre´n et al., 2002)
leading to even more intensive industry-based efforts and regis-
tration and approval of sitagliptin in 2006 (Subbarayan and
Kipnes, 2011). Several additional DPP-4 inhibitors have been
subsequently launched.
What are the take-home messages? Industry-based R&D
efforts were preceded by years of academic research establish-
ing the importance of this pathway in animals and in human
disease. However, for both first-in-class drugs, progress from
initiation of formal drug discovery to approval was still
a decade-long adventure, even with important contributions
from continued academic research and close industry-academic
collaboration. What’s often ignored— but can be gleaned
patents and public company records—is that many additional
clinical stage molecules were discovered and partially devel-
oped, before being terminated for technical (e.g., safety) or stra-
tegic (not viewed as commercially viable) reasons. I estimate that
more than five additional GLP-1 related peptides and ten addi-
tional DPP-4 inhibitors were characterized in early human clinical
trials! It’s also noteworthy that U.S. FDA approval of second or
third-in-class molecules for both mechanisms lagged behind
by 3–6 years. This was largely a consequence of the previously
described regulatory requirements imposed to insure greater
safety.
Along with the successes achieved in the GLP-1 and DPP-4
drug classes were high profile failures, such as torcetrapib and
rimonabant. The late Phase III failure of Torcetrapib, the first
developed CETP inhibitor, was a dramatic example of how off-
target vascular toxicity (mediated by increases in aldosterone)
led to unexpected adverse outcomes rather than the CV benefit
expected from increased HDL cholesterol (Food and Drug
Administration, 2006; Hu et al., 2009). An even more spectacular
failure involved withdrawal of rimonabant, a cannabanoid 1
(CB1) receptor inverse agonist for treatment of obesity, from
the market. Adverse psychiatric effects (no doubt mechanism-
based) proved to be the Achilles heel for CB1. In fact, the demise
of rimonabant incited wholesale retreat from this approach by
companies across the globe (Lee et al., 2009).22 Cell Metabolism 15, January 4, 2012 ª2012 Elsevier Inc.Improving the Odds
Incretin-based therapies are contemporary examples of elegant
approaches harnessing a well-characterized pathway. It can be
argued that the POS for these mechanisms was relatively high
at the stage when industry efforts were ramping up. Yet the
field of cardiometabolic disease is also littered with failures.
Past commercial successes have been generally sufficient to
fund newer R&D efforts, but the aggregate expense and pro-
tracted timelines we face today (even for the most successful
ventures) implies that the current paradigm is not sustainable.
To improve the odds, a paradigm shift must focus on three
strategic goals.
1. Leverage New Technology Platforms
Several newer platforms can provide important target validation
information. Cell-based knockdown or overexpression as well as
in vivo genetic models provide valuable insights. A good
example is the broad use of mouse knockouts to screen for
obesity-related targets (Brommage et al., 2008). However,
compensation by other genes can mask or alter the phenotype
and background strain may also exert major effects (Lariviere
et al., 2001). Thus, results obtained using knockout mice must
be interpreted with caution. In my experience, a mouse pheno-
type of resistance to diet-induced obesity typically does not
translate into favorable pharmacology when the appropriate
tool compound(s) are tested in a similar context. But despite
shortcomings, these technologies can and should still be effi-
ciently used to winnow longer lists of candidate targets and
pathways.
Advances in drug screening and medicinal chemistry technol-
ogies are also paving the way for pursuit of ‘‘intractable’’ targets,
such as small molecule GLP-1 receptor agonists (Sloop et al.,
2010).
Target identification and prioritization can also be augmented
by applying new computational data mining approaches to
preexisting information sources—including genetic data, micro-
array data, proteomic data, etc.—conjoined by integrated
pathway mapping (Yang et al., 2009). One newer application
involves integrating information from genetic mapping with
tissue gene-expression profiling to generate expanded
disease-associated networks (Schadt, 2009). This approach
might soon yield novel drug targets, but the volume of data
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that ‘‘systems approaches are still in their infancy’’ (Schadt,
2009).
Importantly, many of the more ‘‘modern’’ techniques noted
above were not routinely applied before 1995–2000. Therefore,
their impact on net industry output cannot yet be fully assessed.
2. Better Human Validation
Our understanding of human disease has not kept pace with the
abundance of identified target opportunities. Better under-
standing of disease pathogenesis remains essential. For type 2
diabetes, obesity, and CV disease, drug target selection and
prioritization should take human genetics into account (McCar-
thy, 2010; Libby et al., 2011). Moreover, increased POS can be
achieved with selected targets such as PCSK9 where mono-
genic traits affecting LDL cholesterol strongly predict future
clinical efficacy (reviewed by Libby et al., 2011). The application
of metabolite profiling (‘‘metabolomics’’) to larger clinical
samples also provides new insights. Rather than relying on
cross-sectional studies, it is important to incorporate prospec-
tive clinical endpoints. Findings related to diabetes pathogenesis
obtained using mass spectrometry in >2000 blood samples
from the Framingham Offspring cohort illustrate this point
(Wang et al., 2011). Similarly, tissue biobanks with associated
prospective clinical outcomes data can be used to detect critical
pathogenic nodes as exemplified by recent results of osteopon-
tin levels in carotid atherosclerotic lesions (de Kleijn et al., 2010).
3. Apply Translational Medicine Principles
Efficient progression of drug discovery projects toward success-
ful clinical readouts is at the heart of ‘‘translational medicine’’
(Milne, 2009). Information from high-quality human experiments
elucidates next steps in research. Biomarkers that inform target
engagement and early efficacy signals are critical to making
succinct go/no-go decisions. This requires exploiting a full
repertoire of imaging, gene expression profiles, and circulating
markers (including metabolomics). Fortunately, many mecha-
nisms targeting cardiometabolic disease lend themselves to
early efficacy signal detection. For example, 24 hr glucose
profiles can predict longer term glycemic efficacy (HbA1c
lowering). Remember, however, that even ‘‘accepted’’ surrogate
biomarkers for outcomes like HbA1c may have limitations as
illustrated by the unexpected results from ACCORD. Methods
for detecting small changes in human energy balance (intake
or expenditure) that predict future weight loss have also been
perfected (Gaich and Moller, 2011). With better translational
medicine tools and molecular probes in hand, a shift toward
earlier implementation of exploratory human testing (clinical
target assessment) is warranted. For example, a candidate
obesity pathway was examined in humans via continuous infu-
sion of a melanocortin 4 selective agonist peptide over several
days (Greenfield et al., 2009).
Where Do We Go from Here?
Future success requires a closer relationship between industry
and academia as well as active knowledge sharing between
research groups through multiparty partnerships and consortia.
The Innovative Medicines Initiative for Diabetes is an excellent
example. This industry-academic consortium focused on rele-
vant questions pertaining to the regulation of b cell mass and
function (IMIDIA, 2011). Other consortia have the potential forgreat impact on the identification and use of biomarkers across
companies (Milne, 2009). Additional examples of open source
innovation that can facilitate academic-industry collaboration
in identifying novel drug-like molecules are also emerging (Lee
et al., 2011). The focused NIH Center for Advancing Translational
Sciences is being established to foster knowledge-sharing that
can favorably impact both academic- and industry-based
applied research (Bristol, 2011).
Finally, we need to carefully consider the concept of ‘‘disease
stratification.’’ Just as breast cancer is not a single disease, we
must acknowledge and embrace the notion that type 2 diabetes,
obesity, and related comorbid CV conditions are ‘‘syndromes’’
with many distinct underlying molecular causes. This will
undoubtedly result in a shift toward the pursuit of tailored
therapies rather than perseverating with ‘‘once-size-fits-all’’
approaches. However, the feasibility of developing drugs that
target only 10% of the population when CV risk must also be
discharged prior to drug approval remains to be seen.
Metabolic disease research has revealed many compelling
molecular pathways with possible connections to human
disease. Signs of improved productivity for industry-based
R&D efforts are also emerging. But rethinking the current para-
digm, embracing new technologies, and adopting translational
medicine principles are crucial to progress in our field.ACKNOWLEDGMENTS
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